Paweł Wiechno

Statistics

Publications

Citations

6.8K

H-Index

Active since

2007

Affiliations

The Maria Sklodowska-Curie National Research Institute of Oncology(Current)

Centrum Onkologii

University of Ulsan

Ulsan College

Merck & Co., Inc., Rahway, NJ, USA (United States)

Paweł Wiechno is an author at The Maria Sklodowska-Curie National Research Institute of Oncology specializing in medicine, oncology, and castration-resistant prostate cancer therapy.

ORCID

Publications per year

2007–2025

Publications

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

Chris Parker, Sten Nilsson, Daniel Heinrich et al. · New England Journal of Medicine · 2013 · 3.3K citations

Medicine, Nuclear Medicine, Radiation Oncology +17

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

Oliver Sartor, Robert L. Coleman, Sten Nilsson et al. · The Lancet Oncology · 2014 · 491 citations

Medicine, Oncology, Pharmacology +17

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial

Noel W. Clarke, Paweł Wiechno, B. Yа. Alekseev et al. · The Lancet Oncology · 2018 · 409 citations · Full text

Medicine, Oncology, Pharmacology +12

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer

Thomas Powles, James W.F. Catto, Matthew D. Galsky et al. · New England Journal of Medicine · 2024 · 322 citations

Medicine, Surgery, Urology +14

1–5 of 38